KMID : 0614720230660100581
|
|
Journal of Korean Medical Association 2023 Volume.66 No. 10 p.581 ~ p.588
|
|
Pharmacological treatment of Meniere disease
|
|
Park Beom-Sik
Kang Byung-Hong Suh Michelle J.
|
|
Abstract
|
|
|
Background: Despite significant progress in audiology, there is no definitive treatment option for Meniere disease due to its multifactorial etiology.
Current Concepts: The primary treatment goal for Meniere disease is first, to decrease the frequency of symptoms and, second, to minimize the severity of vertigo and hearing loss. Concurrently, the preservation of vestibular and auditory functions should be prioritized. The protection of vestibular and auditory functions should also be considered. Treatment options for Meniere disease include lifestyle modifications, medical treatment, and surgical intervention. Recent treatment algorithms aim to gradually escalate the invasiveness of the treatment to assist in developing a more uniform treatment approach.
Nanomaterials, including nanoparticles and nanocarriers, offer an array of novel diagnostic and therapeutic applications for achieving effective drug delivery into the inner ear of patients with Meniere disease. New treatment drugs, such as SPI-1005 (Sound Pharmaceuticals) are currently under clinical trial. Furthermore, drugs are also being repurposed and investigated for their potential in treating Meniere disease.
Discussion and Conclusion: Developing new drugs and investigating the pathophysiology of Meniere disease for subtyping is emerging. These may direct the future diagnosis and treatment of the disease and facilitate a better understanding of disease mechanisms. Patients with different subtypes of Meniere disease may require different treatment strategies, which can be achieved by personalized therapy, accurate prognosis prediction, and even, disease prevention.
|
|
KEYWORD
|
|
Meniere disease, Dizziness, Endolymphatic hydrops, Drug development
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|